EGFR is a protein that, when mutated or overexpressed, can promote the survival and proliferation of cancer cells. Erlotinib binds to the tyrosine kinase domain of EGFR, inhibiting its activation, which in turn prevents the downstream signaling pathways that lead to cell division and survival. By inhibiting these pathways, erlotinib helps to slow down or stop the growth of cancer cells.
